Their power play is hitting at a very respectful 22

Their power play is hitting at a very respectful 22.9 and there PK has started to improve. Montreal looking to stop the bleeding will play conservative and attack in the neutral zone to try and slow down the Leafs. Toronto can win this game with a physical presence as the Canadiens can be overwhelmed easily from the body. It should be noted that Toronto will not see Montreal’s enforcer G.Laraque as he is serving a suspension, I really see Toronto playing a strong game on both ends attacking with there strengths that Montreal cannot stop with there current roster situation.

For Montreal to win they will need a huge performance from goaltender C.Price who will be see 35 shots on goal.If history holds true we have a tremendous game that should end in dramatic fashion.NHL Free Pick: Toronto Maple Leafs This article is also featured on Touthouse Football Betting Picks. LONDON, Jan 7 (Reuters) - Guidance for Societe deFinancement de l'Economie Francaise's (SFEF) planned five-yeareuro benchmark bond has been set at mid-swaps plus 15 to 20basis points, an official at a bank managing the deal said. Plans for the government-backed senior bond for the SFEF,which was created to help banks overcome the financial crisis,were first unveiled in late December. BNP Paribas, Calyon, HSBC, Natixis and SG CIB have beennamed to manage the sale of the triple-A-rated bond (Reporting by Jane Baird). Boston Bruins general manager Peter Chiarelli took thenecessary steps in securing one of the league's top playmakers Tuesday morning, as he signed 32-year-old center Marc Savard to a seven-year extension, as reported by TSN .Savard, who has been the Bruins leading scorer each of his last three years with Boston, is expected to have an annual cap hit of $4.2 Million.It certainly seems as though Savard gave Boston a bit of a "hometown discount" as No.

91 almost surely could have gotten a more lucrative deal elsewhere. But Boston was where Marc Savard wanted to be, and at the end of the day, this deal is good for all parties involved.This sort of deal has become quite popular in the post-lockout NHL, as players sign longer contracts (generally monetarily front-loaded) as a way to sneak around salary-cap restrictions. There's little doubt that the league is looking for a way to curb these deals, but until the new CBA is negotiated, teams would be stupid not to take advantage of thissizable loop-hole.Along with this latest development, Chiarelli has already secured David Krejci, Milan Lucic, Tuukka Rask, and Tim Thomas to long-term deals in the past six months (not to mention the extensions dished out just yesterday to most of the coaching staff, coupled with the deal coach Claude Julien signed in the offseason).It seems as though Boston's management is doing everything within their power to secure the core of this club for years to come.Apparently, no one consulted "Senior Advisor to the Owner" and former Bruins GM Harry Sinden about this deal."I'm not a fan of his," the surely senile Sinden once quipped, "he's one of those guys who has the batting average but no runs batted in. It's practical, and should be in style until at least the year 2016.An official announcement is expected from the Bruins within the next 48 hours.. DUBLIN, Ireland(Business Wire)Research and Markets( http://) hasannounced the addition of the "Romania Pharmaceuticals and Healthcare Report Q42008" report to their offering. Our Romania Pharmaceuticals and Healthcare Report provides independent forecastsand competitive intelligence on Romania's pharmaceuticals and healthcareindustry.

Romania remains one the most vibrant markets in Central and Eastern Europe(CEE), following growth of over 22 in local currency terms in 2007. The market picked up in Q208, registering growth of 21.3 after3.8 in Q108. The benefits associated with EU regulation should provide an improved businessenvironment over the medium- to long-term, particularly for innovative firms.The first half of 2008 brought mixed results for generics firms. Three of themajor foreign players, Zentiva, Terapia-Ranbaxy, and Krka all experienced ayear-on-year (y-o-y) decline in sales in H108.